What's on this Page
Desonide Brand Names
Desonate | DesOwen | LoKara | Tridesilon | Verdeso
What is Desonide
Desonide is a topical, low-potency synthetic corticosteroid with similar efficacy to hydrocortisone.
It is used to relieve the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Low-potency topical corticosteroids have modest antiinflammatory properties and are usually effective in treating acute inflammatory skin conditions.
Since the stratum corneum is thin on the face and intertriginous areas, low-potency topical corticosteroids are preferred. Low potency topical corticosteroids are also considered the safest for chronic use and are preferred in elderly or pediatric patients.
Commercial products include cream, lotion, foam, gel, and ointment formulations.
Desonide was initially FDA-approved in 1972.
Indications
- atopic dermatitis
- contact dermatitis
- dermatitis
- discoid lupus erythematosus
- eczema
- exfoliative dermatitis
- granuloma annulare
- lichen planus
- lichen simplex
- polymorphous light eruption
- pruritus
- psoriasis
- Rhus dermatitis
- seborrheic dermatitis
- xerosis
Side Effects
- acneiform rash
- adrenocortical insufficiency
- blurred vision
- cataracts
- contact dermatitis
- Cushing’s syndrome
- erythema
- folliculitis
- glycosuria
- growth inhibition
- headache
- hyperglycemia
- hypertension
- hypertrichosis
- hypothalamic-pituitary-adrenal (HPA) suppression
- impaired wound healing
- increased intracranial pressure
- infection
- maculopapular rash
- miliaria
- ocular hypertension
- papilledema
- pruritus
- pseudotumor cerebri
- purpura
- skin atrophy
- skin hypopigmentation
- skin irritation
- skin ulcer
- striae
- telangiectasia
- tolerance
- visual impairment
- withdrawal
- xerosis
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acne rosacea
- acne vulgaris
- breast-feeding
- children
- corticosteroid hypersensitivity
- Cushing’s syndrome
- diabetes mellitus
- fungal infection
- geriatric
- growth inhibition
- herpes infection
- hypothalamic-pituitary-adrenal (HPA) suppression
- increased intracranial pressure
- infants
- infection
- measles
- neonates
- occlusive dressing
- ocular exposure
- ophthalmic administration
- perioral dermatitis
- pregnancy
- skin abrasion
- skin atrophy
- tuberculosis
- varicella
- viral infection
Interactions
- Metyrapone
Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone. Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.
